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Abstract The structure of the glycosomal glyceraldehyde-3-
phosphate dehydrogenase (gGAPDH) from Trypanosoma cruzi
complexed with chalepin, a natural product from Pilocarpus
spicatus, has been determined by X-ray crystallography to 1.95
A& resolution. The structure is in the apo form without cofactors
in the subunits of the tetrameric gGAPDH in the asymmetric
unit. Unequivocal density corresponding to the inhibitor was
clearly identified in one monomer. The final refined model of the
complex shows extensive conformational changes when com-
pared with the native structure. The mode of binding of chalepin
to gGAPDH and its implications for inhibitor design are
discussed. * 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Some protozoan parasites of the family Trypanosomatidae
cause a wide variety of severe diseases such as the American
trypanosomiasis known as Chagas’ disease. Some 100 million
persons ^ a quarter of all the inhabitants of Latin America ^
are at risk of contracting the disease and an estimated 16^18
million people are infected [1]. Chagas’ disease is caused by
infection with the parasite Trypanosoma cruzi. It is transmit-
ted by the blood-sucking Triatomine insects, through blood
transfusions or congenitally from infected mothers. No e¡ec-
tive treatment is available for the disease [2].
The modern approach of target-directed drug development
involves the identi¢cation of suitable enzymes taking part in
essential metabolic pathways of pathogens. Several peculiar-
ities in the biology of trypanosomatids have been suggested to
be exploitable for drug design purposes [3]. Trypanosomatids
are highly dependent on glycolysis for ATP production [4,5]
and the in silico modeling of the pathway has indicated the
reaction catalyzed by glycosomal glyceraldehyde-3-phosphate
dehydrogenase (gGAPDH) as one of the preferred steps for
inhibition [6,7]. The enzyme catalyzes the oxidative phosphor-
ylation of D-glyceraldehyde-3-phosphate into 1,3-diphospho-
glycerate in the presence of NADþ and inorganic phosphate.
Structural studies of the enzymes from Trypanosoma brucei [8]
and Leishmania mexicana [9] have shown di¡erences in the
NADþ cofactor binding pocket when compared with the hu-
man homologue, which lead to the design and synthesis of
several inhibitors focusing on this site [10^13]. Aiming at
the design of novel classes of anti-chagasic drugs, the structure
of the T. cruzi gGAPDH was determined and described else-
where [14]. Computational search procedures [15] and exten-
sive screening of plant extracts through the enzymatic inhib-
itory assays have been performed in the search for promising
lead compounds [15^17]. Several coumarins were found as the
most promising class of substances from natural sources with
signi¢cant gGAPDH inhibitory activity. Amongst them is
chalepin (Fig. 1), a coumarin extracted from Pilocarpus spica-
tus, which has an IC50 (inhibitor concentration required for
50% inhibition of enzymatic activity) of 64 WM [17].
In order to elucidate the mechanism of inhibition and the
speci¢c mode of binding of this inhibitor, and to elicit further
improvement of this molecule through structure-based drug
design, we present here the crystallographic structure of
gGAPDH from T. cruzi complexed with chalepin.
2. Materials and methods
2.1. Preparation and puri¢cation of T. cruzi gGAPDH
Recombinant T. cruzi gGAPDH was prepared and puri¢ed accord-
ing to a previously reported procedure [14].
2.2. Extraction, isolation and identi¢cation of chalepin
The air-dried powdered stem of P. spicatus (Rutaceae) was exhaus-
tively extracted with organic solvents (hexane, CH2Cl2 and MeOH)
through percolation processing at room temperature. Crude extracts
were obtained after evaporation of the solvents under reduced pres-
sure at 40‡C. The hexane extract (PSSH, 6.0 g) was fractionated
through liquid^liquid partition with hexane^methanol^water
(10:9:1) followed by ethyl acetate^methanol^water (1:1:1) and buta-
nol^methanol^water (1:1:2). The ethyl acetate fraction (PSSH/A, 1.3 g)
was chromatographed on a silica gel column using a step gradient of
hexane and ethyl acetate. Successive £ash chromatography of the
fraction eluted with 20^30% hexane/ethyl acetate allowed the isolation
of the 6-(1,1-dimethylallyl)-2-(1-hydroxy-1-methylethyl)-2,3-dihydro-
7H-furo[3,2-g]chromen-7-one, a coumarin known as chalepin (45
mg). The structure of chalepin was deduced on the basis of its spectral
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data (1H and 13C nuclear magnetic resonance and mass spectrometry),
which were con¢rmed by comparative analysis with the literature
values [18].
2.3. Enzymatic inhibition studies
The enzymatic activities of T. cruzi gGAPDH and its human ho-
mologue and the inhibitory activity of chalepin against these enzymes
have been determined according to a previously reported procedure
[17], using the forward reaction.
The IC50 was determined empirically. A wide range of concentra-
tions (10^100 Wg/ml) of inhibitor were tested at substrate and cofactor
saturating conditions. The percentage of remaining activity was calcu-
lated by comparison with an inhibitor-free control experiment.
The chalepin showed no inhibition of human GAPDH activity
while it showed an IC50 of 64 WM against T. cruzi gGAPDH, as
mentioned above.
2.4. Co-crystallization assays
Co-crystallization assays were carried out using a protein solution
at 8 mg/ml in 0.1 M TEA pH 7.6, 1 mM NADþ, 1 mM DTT, 1 mM
PMSF, 1 mM EDTA, 1 WM leupeptin and 1 WM pepstatin pre-incu-
bated with 5 mM of inhibitor and 10% (v/v) of acetonitrile. Crystals
of the complex gGAPDH^chalepin were grown at 22‡C by vapor
di¡usion, against a reservoir solution of 0.1 M sodium cacodylate
pH 6.9^7.1, with 0.1 M calcium acetate, 16^18% of polyethylene gly-
col 8000, in a microgravity environment during £ight STS-91 of the
NASA US Space Shuttle program. Mechanical damage upon landing
and transport of crystals resulted in few crystals being available for
data collection.
2.5. Data collection and processing
Crystals of the gGAPDH^chalepin complex were £ash-cooled to
100 K in an Oxford Cryostream Cooler. The cryoprotectant solution
used consists of 20% polyethylene glycol 400 added to the above
described reservoir solution. The X-ray source was a Rigaku RU-
200 rotating anode generator operating at 50 kV/100 mA. Di¡raction
intensities were collected with an R-AXIS II image plate, using the
rotation method [19]. Data processing was carried out with programs
DENZO and SCALEPACK [20]. Final electron density maps for each
collected data set revealed that only in one crystal the inhibitor could
be unambiguously modelled. Data collection and processing statistics
for this data set are summarized in Table 1. The experiment had to be
interrupted after 120 frames due to loss of cryogenic protection. All
available and well measured data were included in the re¢nement, on
the basis that the program used does take care adequately of low
intensity data, through proper weighting of weak observations. The
criterion used to decide on the cut-o¡ of the data was to limit the
resolution when I/c(I) was above 1.0 and the Rmerge was below 50%.
Crystals belong to the space group P21 with unit cell parameters
a=82.08 A , b=84.97 A , c=105.24 A and L=96.32‡. The analysis of
crystal contents indicates one tetramer per asymmetric unit and a Vm
value of 2.34 A 3/Da.
2.6. Structure determination and re¢nement
The structure of the chalepin complex was determined by molecular
replacement, using the program AMoRe [21]. The native gGAPDH
structure without ligands or water molecules was used as the search
model. Using di¡raction data in the resolution range 15.0^4.0 A , the
top solution showed correlation coe⁄cient of 61.3% and Rfactor of
35.7%. The rotated and translated model was re¢ned using REFMAC
[22], the electron density maps and omit maps were calculated using
FFT [23] and OMIT [24], respectively, all from the CCP4 suite of
programs [25]. Manual rebuilding of the macromolecular model and
graphics visualization were performed using the O software [26]. The
crystallographic Rfactor and Rfree;3% values, as well as the stereochem-
istry quality of the model (program PROCHECK [27]), were con-
stantly monitored during the course of the re¢nement.
The ¢rst cycle was a rigid body re¢nement, with only the quater-
nary structure of the model tetramer being allowed to change while
the four individual subunits were held as rigid bodies. This re¢nement
produced a Rfactor of 0.398 and Rfree of 0.405. 2Fobs3Fcalc and
Fobs3Fcalc electron density maps calculated from this model showed
no density in the cofactor binding sites which could be interpretable as
NADþ. This fact clearly indicated the interference of the inhibitor
over the enzyme. Thus, the following cycles of restrained crystallo-
graphic re¢nement were carried out without non-crystallographic
symmetry to search for any bound inhibitor to the tetramer. A di¡er-
ence (Fobs3Fcalc) electron density map calculated after 10 cycles of
automated restrained re¢nement showed density in the active site of
the C subunit resembling the inhibitor. At this point, the Rfactor was
0.252 and Rfree was 0.322. After several iterative cycles of restrained
re¢nement of the atomic coordinates followed by visual manipulation,
water molecules were automatically built into the model using the
program ARP [28]. After inclusion of 630 water molecules the
Rfactor dropped to 0.209 and Rfree to 0.282. At this stage a molecule
of chalepin was manually built into the electron density observed at
the C subunit active site. The ¢nal cycles of re¢nement included the
addition of another 307 waters, as well as the re¢nement of partial
occupancies for the inhibitor and the two alternative conformations
for the ^SH group of active site Cys166 of subunit C. The results are
summarized in Table 2.
2.7. Protein data bank accession number
The atomic coordinates of the T. cruzi gGAPDH^chalepin co-crys-
tal structure and the structure factor amplitudes have been deposited
with the Protein Data Bank under ID code 1K3T.
3. Results and discussion
3.1. Quality of the structure
The ¢nal 2Fobs3Fcalc electron density maps calculated for
the gGAPDH^chalepin complex show good quality (Fig. 2).
The stereochemistry of the structure is, in general, quite sat-
isfactory, with more than 99% of the residues showing torsion
angles in the favorable regions of the Ramachandran diagram
[29]. Only Ala73 from the C subunit and Val255 from all sub-
units are in unfavorable regions. Ala73 is located in a £exible
loop at the N-terminal, which shows poor electron density,
Fig. 1. Chalepin.
Table 1
Statistics of X-ray data collection and processing
Rotation angle 1.0‡
Total number of frames 120
Total collected re£ections 195 798
Number of unique re£ections 81 630
Resolution limit 1.95 A
Completeness 77.9% [38.1%]
Rmerge 10.7% [48.3%]
I/c(I) 6.78 [1.1]
Redundancy 2.4 [1.6]
The values in brackets correspond to the last resolution shell (2.02^
1.95 A )
Table 2
Final re¢nement statistics
Resolution range 15^1.95 A
Amino acid residues per monomer 359
Water molecules 937
Inhibitor molecule in the a.u. 1
Rfactor 0.201
Rfree;3% 0.280
RMS bond deviations 0.015 A
RMS angle deviations 3.1‡
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causing di⁄culties to appropriately model its torsion angles.
Val255 is located in a loop between two consecutive L-strands
and its uncommon conformation is conserved in all other
GAPDH structures available [8,9,14,30,31] and is important
to maintain the correct positioning of the active residue Cys166
with respect to the nicotinamide ring of the NADþ cofactor
during catalysis.
The average temperature factor values for the main chain
and all atoms of the 359 residues from each subunit are,
respectively, 24.3 A 2 and 25.2 A 2, to the A subunit, 29.9 A 2
and 30.7 A 2, to the B subunit, 42.8 A 2 and 43.3 A 2, to the C
subunit and 25.0 A 2 and 26.1 A 2, to the D subunit. The
average temperature factor value for all atoms of chalepin is
70.8 A 2. The higher values of the average temperature factor
observed for the C subunit re£ect the static disorder resulting
from the partial occupancy of the inhibitor (85%) at its active
site. Analysis of the crystal packing shows that the NADþ
binding domain of subunit C has no lattice contacts, compat-
ible with alternative domain rotations.
3.2. Structural di¡erences between gGAPDH complexed with
chalepin (apo form, without NAD+) and the native holo
form
The four individual subunits of the gGAPDH tetramer are
related to each other by a 222 non-crystallographic symmetry.
Each subunit is composed of two domains: the NADþ bind-
ing domain, comprising residues 1^150 at the N-terminal and
residues 331^359 at the C-terminal; and the catalytic domain,
Fig. 2. Electron density omit maps (2Fobs3Fcalc) of the GAPDH^chalepin complex, close to the active site, contoured at 1.3c level. Unambigu-
ous density for the natural product inhibitor is seen. Figure produced with the program PyMOL Molecular Graphics System - DeLano Scien-
ti¢c.
Fig. 3. A: Superposition of the native T. cruzi gGAPDH structure (thin ribbon) and chalepin complex (thick ribbon) with the inhibitor dis-
played. The catalytic domain (left) was included in the superposition protocol. B: Close-up of the active site with ligands. The NADþ is bound
to the native structure whereas the chalepin is bound in the complex structure. The clash observed in the region of the nicotinamide moiety of
NADþ explains why the binding of the inhibitor implies in the displacement of the cofactor, therefore stabilizing the apo structure of the en-
zyme. Figure produced with the program Web Lab Viewer (Molecular Simulations Inc.).
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comprising residues 151^330. The tetramer of GAPDH is
formed exclusively through contacts between all four catalytic
domains, constituting a rigid core of the tetrameric particle
that remains virtually unchanged in both native and complex
structures. The displacement of the NADþ cofactor by the
binding of the inhibitor induces the holo to apo transition,
represented predominantly by an approximate rigid-body ro-
tation of 4‡ of the NAD binding domain of each subunit
relative to the structurally conserved catalytic domain (Fig. 3).
Other internal modi¢cations of the NADþ binding domain
are also present. This feature has previously been observed
in the apo and holo forms of GAPDH and liver alcohol de-
hydrogenase enzymes from other sources [32^34]. The authors
suggested that the overall e¡ect of this conformational change
is to expose the cofactor and active site to solvent in the apo
form and provide additional shield of the cofactor and active
site from solvent in the holo form. Indeed, the tetrameric holo-
enzyme shows a solvent-accessible surface area of 46 051 A 2
while the apo-enzyme has a surface area of 49 152 A 2. The
solvent-accessible surface buried upon ligand binding at sub-
unit C is 205 A 2.
3.3. gGAPDH^chalepin interaction architecture
Of the possible 525 A 2 of solvent-accessible surface area in
the free inhibitor, 209 A 2 are exposed to solvent in the com-
plex and 316 A 2 are buried upon binding. The analysis of the
complex shows three important interacting groups from cha-
lepin (Fig. 4). The carbonyl oxygen from lactonic group in-
teracts with residue Thr167 by hydrogen bonds mediated by a
water molecule W739. The 1,1-dimethylallyl group interacts by
hydrophobic contacts with catalytic residue Cys166, which has
to undergo a conformational change through a rotation of M1,
Fig. 4. Stereoview of the overall mode of binding of chalepin to gGAPDH active site. Figure produced with the program Web Lab Viewer
[Molecular Simulations Inc.].
Fig. 5. View of the chalepin binding site. The neighboring regions of the 1,1-dimethylallyl group, which remain unoccupied after binding of the
inhibitor, show charged residues which can be exploited in the design of new chalepin derivatives. Molecular surface of the gGAPDH generated
with the program Web Lab Viewer [Molecular Simulations Inc.].
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in order to accommodate the positioning of the inhibitor at
the active site. Indeed, the ¢nal electron density maps show
the two alternative conformations of Cys166, one of them ap-
parently connecting to the inhibitor. This is an artifact, since
the side chain of this residue is at the native conformation
only when the inhibitor is absent. Therefore, the evident two
conformations of the Cys166 side chain guarantee that the
inhibitor has to have partial occupancy. Finally, the oxygen
atom from the benzo-dihydrofuran group interacts with resi-
due Arg249 through a hydrogen bond mediated by water mol-
ecule W813. The 1-hydroxy-1-methylethyl group interacts
weakly with the residue Asp210 by hydrogen bond mediated
by a water molecule W812.
3.4. Implications for drug design approach
Based on this analysis, modi¢cations in the chalepin inhib-
itor can be suggested by molecular modeling studies. At the
1,1-dimethylallyl binding site it is evident (Fig. 5) that there
are neighboring regions with charged residues, which remain
unoccupied after binding of the inhibitor. It is therefore pos-
sible to design the replacement of the 1,1-dimethylallyl group
by substituents containing heteroatoms like nitrogen, oxygen
or halogens. These modi¢cations could enable the formation
of new dipole^dipole interactions resulting in energetic gain
notably greater than the hydrophobic interactions observed in
the crystal structure. Besides, Souza et al. [14] suggest that the
substitution of Asp210 (T. cruzi) by Leu194 (human) brings a
new target for selective inhibition. The chalepin 1-hydroxy-1-
methylethyl group does not interact e⁄ciently with the pro-
tein. The introduction of a linker arm of one or two carbon
atoms may cause a closer contact between the chalepin hy-
droxyl and the Asp210 delta2 oxygen atom, producing more
e¡ective polar interactions and increasing speci¢city for the
parasitic enzyme. New proposed coumarin derivatives are
being synthesized and tested against T. cruzi gGAPDH to
evaluate these possibilities.
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